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Introduction
Dermatology Life Quality Index (DLQI) was the first and, to date, is the most commonly used health-related quality of life (HRQoL) measure in dermatological settings. [1] [2] [3] Over the past two decades, it has pervaded the management of psoriasis patients in multiple ways. It serves as an easy-to-use instrument and a useful benchmark to evaluate treatment efficacy both in routine clinical work and in a variety of researches. 4 It is by far the most commonly applied HRQoL tool in randomized controlled trials for interventions in psoriasis. 5 According to the European consensus, DLQI is among the diagnostic criteria of moderate-to-severe psoriasis to determine which patients need to be offered systemic treatments. [6] [7] [8] Furthermore, in many European countries, includ-biological therapy alongside the Psoriasis Area and Severity Index (PASI).
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The DLQI is a simple self-administered questionnaire that assesses the impact of a skin disease on HRQoL of the patient over the last week. 1 The 10-item instrument includes the following six dimensions of HRQoL: symptoms and feelings, daily activities, leisure, work and school, personal relationships and treatment. Each question is scored on a 4-point scale ('not at all' = 0, 'a little' = 1, 'a lot' = 2 and 'very much' = 3). Moreover, eight questions have 'not relevant' response (NRR) options that are given the same zero scores as 'not at all' responses. Scores of individual items are added to yield a total score ranging from 0 to 30, where a higher score represents a greater impairment of HRQoL. A NRR option in up to 80% of the questions of a HRQoL measure is rather unusual, especially in case of such a short questionnaire. Nevertheless, the literature regarding the occurrence of NRRs on the DLQI is scarce and inconsistent. The overwhelming majority of DLQI studies, including validation studies, are neglected to report the number of NRRs on the DLQI items or the proportion of patients with NRRs. 1, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] On the other hand, studies from a variety of countries noted very high, and others, on the contrary, reported almost no NRRs in most questions of the DLQI. [31] [32] [33] [34] [35] [36] [37] [38] Given that all NRRs are scored as 0 (equal to 'not at all' responses), they may artificially improve the DLQI score of patients who give at least one NRR in any item. The large number of NRRs may implicate a problem with the content validity of the DLQI. Despite the obvious anomaly in this answer option and its scoring, no study has provided a detailed analysis on NRRs on the DLQI, so far. The objective of this study was thus to explore the occurrence of NRRs on the DLQI in a large sample of psoriasis patients and to examine the effect of several socio-demographic and clinical factors on giving NRRs.
Methods

Study design
Data from two cross-sectional questionnaire surveys among psoriasis patients aged 18 or above were combined. Detailed methodology of the studies has been published elsewhere. [39] [40] [41] [42] [43] Both surveys have been performed in a paper-based fashion at academic dermatology clinics in Hungary. The first study was carried out between September 2012 and May 2013 at two clinics: Semmelweis University, Department of Dermatology, Venereology and Dermatooncology (hereinafter referred as clinic #1) and University of Debrecen, Department of Dermatology (hereinafter referred as clinic #2). The survey involved 200 consecutive outpatients with moderate-to-severe psoriasis. The second study, undertaken from September 2015 to June 2016 at clinic #1, enrolled 238 psoriasis patients regardless of disease severity. Consecutive outpatients as well as patients hospitalized due to psoriasis were recruited to complete the questionnaire.
Patient population
A total of 438 psoriasis patients filled in the two questionnaire surveys. As clinic #1 participated in both studies (99 patients in the first survey and 238 patients in the second survey), we tested whether an overlap would exist between the two patient populations. We identified four patients who completed both surveys; therefore, their data were included once (the later). Of the 434 patients left after exclusion, further six patients were excluded, for whom a total DLQI score could not be calculated due to missing responses. Thus, the valid patient population for analysis consisted of 428 psoriasis patients.
Outcome measures
DLQI was applied to measure dermatology-specific HRQoL. A description of the DLQI and its scoring is provided in the Introduction. General health status and HRQoL were measured by the Hungarian version of the EQ-5D-3L (hereinafter referred as EQ-5D) questionnaire, which showed a good validity and responsiveness in psoriasis. [43] [44] [45] [46] It consists of two measures, the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system is based on the following five dimensions of HRQoL: mobility, self-care, usual activities, pain/ discomfort and anxiety/depression. Patients may report no problems, some or moderate problems or extreme problems in each dimension, which result in a total of 3 5 = 243 possible health states. In the lack of Hungarian national value set, EQ-5D index scores were calculated according to the UK one developed by Dolan, 47 so values ranged between À0.594 and 1. The EQ VAS records the respondent's self-rated health on a 20-cm vertical line, ranging from 0 (worst imaginable health state) to 100 (best imaginable health state). Disease severity was evaluated by PASI that grades the severity of psoriasis by the presence of erythema, induration and scaling and the extension of the lesions with respect to four body regions: head, trunk, upper and lower extremities. 48 The PASI total score ranges from 0 to 72, where a higher score corresponds to a higher disease severity.
Data analysis
Descriptive statistics were computed for all socio-demographic and clinical variables as well as for HRQoL outcomes. Frequencies of responses in each DLQI item and mean DLQI scores were calculated. Patients were stratified into subgroups according to the banding DLQI system proposed by Hongbo et al. (DLQI scores 0-1 = no effect; DLQI scores 2-5 = small effect; DLQI scores 6-10 = moderate effect; DLQI scores 11-20 = very large effect; DLQI scores 21-30 = extremely large effect). 49 Two different approaches were used to analyse the occurrence of NRRs on the DLQI. First, the proportion of NRRs was calculated for each item of the DLQI with the exception of the first and second, which offer no NRR options. Secondly, the total number of NRRs per patient was determined. This value was measured on a scale from 0 to 8. Due to skewed distribution of data, we applied Kruskal-Wallis test and Dunn-Bonferroni post hoc test to compare DLQI, PASI, EQ-5D and EQ VAS scores between groups of patients classified according to their number of NRRs. Multivariate logistic regression was applied to determine predictors of providing NRRs. An odds ratio (OR) and its 95% confidence interval (CI) were calculated for each variable. The associations between gender and the number of NRRs along the DLQI items were analysed by chi-squared test. All the statistical tests were two-sided, and a P < 0.05 was considered statistically significant. Data were analysed using IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp. (2013).
Results
Characteristics of the patient population
Mean age of the 428 psoriasis patients was 49.2 AE 14.3 years (min. 18, max. 86 years), and 65% were males (Table 1) . Almost one-third of the patients had a college or university degree, and less than half of them worked in a full-time job. Similar to the general population in Hungary, higher rate of male patients worked (either full time or part time) in our sample, compared to females (62.6% vs. 44.7%, P < 0.001). There was no significant difference among women and men concerning education (P = 0.628). Mean disease duration was 19.9 AE 12.3 years, and there were merely six patients who had been diagnosed less than a year before participating in the study. More than 80% of the patients presented with moderate-to-severe psoriasis. Mean PASI, DLQI, EQ-5D and EQ VAS scores of the total sample were 8.4 AE 9.5, 6.8 AE 7.4, 0.74 AE 0.28 and 69.1 AE 14.0, respectively. Distribution of patients according to DLQI bands is presented in Table 1 . The majority of the patients were treated by biologics (43.7%), while 25% received systemic non-biological and 24.1% topical therapy only. There were 31 patients (7.2%) who received no medical treatment at the time of the survey. Most of them had a PASI score of over 10 and were right before the initiation of systemic therapy.
Descriptive results of 'not relevant' responses
Concerning items 6 (sport), 9 (sexual difficulties) and 7 (working or studying), 28.4%, 16.4% and 14% ticked a NRR, respectively (Table 2 ). In contrast, less than 3% of answers were NRRs in items 4 (clothes), 10 (treatment difficulties) and 5 (social activities).
Of the 428 patients, 166 (38.8%) gave at least one NRR on the DLQI. Of these, there were 84 patients (19.6%) with one NRR, 49 (11.5%) with two NRRs, 22 (5.1%) with three NRRs, seven (1.6%) with four NRRs, one (0.2%) with five NRRs, two (0.5%) 'Not relevant' responses on DLQI with six NRRs, none with seven NRRs and one (0.2%) with eight NRRs. Item 6 was ticked by the majority of patients with only one NRR (61.9%), followed by items 9 (20.2%) and 7 (15.5%).
By increasing the number of NRRs, the percentage of item 6 gradually decreases, while those of items 7, 8 and 9 clearly rise (Fig. 1) . The proportion of NRRs per DLQI score bands is depicted in Fig. 2 . Overall, 28% of patients with DLQI scores of 0 or 1 had at least one NRR. Corresponding percentages for patients with DLQI total scores of 2-5, 6-10 and 11-20 were 38%, 52% and 53%, respectively. The proportion of NRRs in patients with a DLQI ≥ 21 was 13%, on average.
Determinants of 'not relevant' responses
Mean DLQI scores of patients with 0, 1 and 2 ≤ NRRs were 6.5 AE 8.0, 7.2 AE 6.6 and 7.3 AE 6.0, respectively (P = 0.049). This trend that patients with higher DLQI scores had more NRRs can be seen in Fig. 2 as well, with the exception of the group who had a result of more than 20 points on the DLQI. Patients with 0, 1 and 2 ≤ NRRs showed mean PASI scores of 6.5 AE 8.0, 9.3 AE 9.7 and 11.3 AE 10.5, respectively (P < 0.001). Worse general HRQoL (lower EQ-5D and EQ VAS scores) was also associated with a higher number of NRRs (P < 0.001). Pairwise comparisons between groups confirmed these differences for PASI, EQ-5D and EQ VAS ( Table 3) .
In a multivariate logistic regression, several socio-demographic and clinical characteristics were found to have a significant impact on NRRs ( 1.055) were related to an increased odds of the occurrence of NRRs.
To identify which DLQI items are responsible for the difference between women and men, we compared responses of these two groups according to DLQI items ( Table 5 ). The gender difference in providing NRRs was present in items 5 (social activities), 9 (sexual difficulties) and 10 (treatment difficulties) (P = 0.008, P < 0.001 and P = 0.044, respectively). Items 6 (sport) and 8 (interpersonal problems) also demonstrated a trend towards significance (P = 0.056 and P = 0.058).
Discussion
In the present study, we analysed the occurrence of NRRs on the DLQI in a large sample of psoriasis patients and revealed that DLQI total score, PASI and several socio-demographic factors affected the number of NRRs given by a patient. We believe that our study provides three major findings.
Firstly, 38.8% of psoriasis patients provided at least one NRR. Furthermore, more patients with DLQI scores of 6 to 20 had at least one NRR than those who did not. This suggests that certain items of the DLQI are not important for a significant number of psoriasis patients. Secondly, as NRRs are scored as being 0, the higher number of NRRs is expected to yield a lower DLQI total score. Yet, evidence from our study testifies the contrary; the higher the DLQI score, the more NRRs are ticked (Fig. 2) . The high rate of psoriasis patients with NRRs and the unexpected inverse association between DLQI score and the number of NRRs indicate a content validity problem of the measure. This is supported by the fact that patients with more NRRs had more severe psoriasis (i.e. higher PASI scores). By eliminating DLQI items that were answered NRRs in the calculation of the total score and then converting these raw scores to scores on a 0 to 30 scale, the mean total DLQI score of the 166 patients with NRRs in our sample would increase from 7.23 to 8.94 (P < 0.001). The rise in DLQI score is more prominent in the age group of >65 years (n = 46), whose mean DLQI total score would rise from 7.41 to 10.15 points (P < 0.001). Thirdly, we observed that some socio-demographic groups tended to provide more NRRs. In our study, these groups were elderly, females, those not working full time and less educated patients. The gender difference is particularly important considering the fact that in large European registries, a higher proportion of men with psoriasis are treated with systemic therapy. 11, 50 Nevertheless, more studies with larger sample sizes are required to confirm the generalizability of these findings. 'Not relevant' responses on DLQI
In consistent with the literature, NRRs were the most common in the items of sport, sexual difficulties and working or studying. [31] [32] [33] [34] [36] [37] [38] It appears that these items are more often not relevant to elderly psoriasis patients compared with their younger peers. Nevertheless, psoriasis is a lifelong condition, and a HRQoL instrument should be relevant for every patient regardless of age. This is becoming more important with the increasingly ageing population in the developed countries. A further, very important problem about items 6 (sports) and 9 (sexual difficulties) is that the DLQI assesses the impact of a skin disease on HRQoL of the patient over the last week. On the one hand, there are many arguments in favour of applying a 1-week time frame; for example, the shorter recall period can be more sensitive to recent changes in health status, or less recall bias may occur. 51 On the other hand, many people, also among members of the general population, are not involved in these activities on a weekly basis. Thus, if the DLQI covered a longer time span, items 6 and 9 would be more likely relevant for a higher proportion of patients, and they might report a problem in these items, too. Limitations of the current study include the following. First, despite the large sample size, less than 10 NRRs were reported in some items of the DLQI and only a few patients reported more than two NRRs. However, a heterogeneous psoriasis patient population was recruited both in terms of socio-demographic and clinical characteristics, which was excellent for the purposes of the study. Secondly, some authors have addressed that patients may misunderstand the term 'not relevant' and cannot judge between 'not at all'. 31, 32 We have no data regarding how many patients were not able to make a clear difference between the NRR and the 'not at all' answer options on the DLQI. For example, none of the 31 patients who were not treated at the time of the survey provided a NRR on item 10 (treatment), or of the 19 unemployed patients in our study, six marked any NRR in the questionnaire, only one of which occurred in the working/ studying item. Based on these, the actual rate of NRRs could be overestimated or even underestimated in the current study. The term 'not relevant' is translated differently in other language versions of the DLQI, which may, in part, explain the variances in the rates of NRRs across countries [e.g. German: 'betrifft mich nicht' (=it does not concern me), Hungarian: 'nem vonatkozik € Onre' (=it is not relevant for you), Italian: 'Non riguarda il mio caso' (=It does not affect my case), Swedish -'Ej till€ ampligt' (=Not applicable)]. 52 This draws the attention to the presence of systematic measurement bias in multicountry studies in which the DLQI is filled in by patients with different languages. At the time the DLQI was developed in the early 1990s, the aim of HRQoL assessment was to quantify the quality of life loss experienced by patients. Being the first dermatology-specific HRQoL measure, it brought a paradigm shift in dermatological care, and its merits should not be overlooked. 53 In the context of the present paper, NRRs may be useful, for example, to identify patients who are unemployed or do not go in for sport. Yet, very few studies reported on the number of NRRs and exploited this additional information provided by the DLQI. [31] [32] [33] [34] [35] [36] [37] [38] Over the past two decades, owing to advances in therapy such as biological drugs, the DLQI has become a reference point not only for medical but also for financial decision-making. Currently, the DLQI is widely used in diagnostic criteria for moderate-to-severe psoriasis -(body surface area >10 or PASI > 10) and DLQI > 10 -and for reimbursement decision-making regarding biologics. [7] [8] [9] [10] 54 There is, however, a growing body of the literature questioning the feasibility and pointing out the inherent limitations of the DLQI as a HRQoL measure. In previous studies, Rasch analysis and factor analysis could not confirm its 16, 20, 34, [55] [56] [57] [58] [59] Another study found discrepancies between DLQI scores and time trade-off utility values, suggesting that HRQoL in two patients with identical DLQI scores might be significantly different, while patients whose DLQI scores differ larger than the minimal clinically important difference may be equal. 60, 61 Considering the number of jurisdictions, in which the DLQI is used in national guidelines, including the European S3-Guidelines on the systemic treatment of psoriasis vulgaris, [7] [8] [9] [10] [11] [62] [63] [64] [65] [66] the amount of patients affected worldwide may be very large. Our results, taken together with other findings in the literature, suggest that the applicability of the DLQI in the management of psoriasis patients may be called into question.
